vs
Capitol Federal Financial, Inc.（CFFN）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Capitol Federal Financial, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.6倍（$57.7M vs $35.5M），Capitol Federal Financial, Inc.净利率更高（34.9% vs -304.2%，领先339.1%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 12.1%）
国会联邦储蓄银行（CapFed）成立于1893年，是获得联邦特许并承保的储蓄银行，总部位于堪萨斯州托皮卡。该行目前共有51个网点，覆盖堪萨斯城都会区的堪萨斯州与密苏里州两侧，为个人及企业提供各类金融服务，其控股公司国会联邦金融 Inc.在纳斯达克挂牌上市。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CFFN vs RXRX — 直观对比
营收规模更大
CFFN
是对方的1.6倍
$35.5M
净利率更高
CFFN
高出339.1%
-304.2%
两年增速更快
RXRX
近两年复合增速
12.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.7M | $35.5M |
| 净利润 | $20.1M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 34.9% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFFNRXRX
| Q1 26 | $57.7M | — | ||
| Q4 25 | $56.8M | $35.5M | ||
| Q3 25 | $54.6M | $5.2M | ||
| Q2 25 | $50.7M | $19.2M | ||
| Q1 25 | $48.8M | $14.7M | ||
| Q4 24 | $46.9M | $4.5M | ||
| Q3 24 | — | $26.1M | ||
| Q2 24 | $45.0M | $14.4M |
净利润CFFNRXRX
| Q1 26 | $20.1M | — | ||
| Q4 25 | $20.3M | $-108.1M | ||
| Q3 25 | $18.8M | $-162.3M | ||
| Q2 25 | $18.4M | $-171.9M | ||
| Q1 25 | $15.4M | $-202.5M | ||
| Q4 24 | $15.4M | $-178.9M | ||
| Q3 24 | — | $-95.8M | ||
| Q2 24 | $9.6M | $-97.5M |
毛利率CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | 44.4% | -304.8% | ||
| Q3 25 | 42.2% | -3327.6% | ||
| Q2 25 | 42.6% | -916.8% | ||
| Q1 25 | 39.5% | -1297.9% | ||
| Q4 24 | 40.7% | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | 34.7% | -697.4% |
净利率CFFNRXRX
| Q1 26 | 34.9% | — | ||
| Q4 25 | 35.7% | -304.2% | ||
| Q3 25 | 34.5% | -3135.3% | ||
| Q2 25 | 36.2% | -894.2% | ||
| Q1 25 | 31.6% | -1373.3% | ||
| Q4 24 | 32.9% | -3935.5% | ||
| Q3 24 | — | -367.5% | ||
| Q2 24 | 21.4% | -676.6% |
每股收益（稀释后）CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | $0.16 | $-0.17 | ||
| Q3 25 | $0.14 | $-0.36 | ||
| Q2 25 | $0.14 | $-0.41 | ||
| Q1 25 | $0.12 | $-0.50 | ||
| Q4 24 | $0.12 | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | $0.07 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $1.0B | $1.1B |
| 总资产 | $9.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CFFNRXRX
| Q1 26 | $2.5M | — | ||
| Q4 25 | $232.6M | $743.3M | ||
| Q3 25 | $252.4M | $659.8M | ||
| Q2 25 | $175.0M | $525.1M | ||
| Q1 25 | $340.4M | $500.5M | ||
| Q4 24 | $170.3M | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | $317.8M | $474.3M |
总债务CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益CFFNRXRX
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $1.1B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $919.1M | ||
| Q1 25 | $1.0B | $933.9M | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | — | $524.6M | ||
| Q2 24 | $1.0B | $584.4M |
总资产CFFNRXRX
| Q1 26 | $9.8B | — | ||
| Q4 25 | $9.8B | $1.5B | ||
| Q3 25 | $9.8B | $1.4B | ||
| Q2 25 | $9.7B | $1.3B | ||
| Q1 25 | $9.7B | $1.3B | ||
| Q4 24 | $9.5B | $1.4B | ||
| Q3 24 | — | $726.5M | ||
| Q2 24 | $9.6B | $775.9M |
负债/权益比CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | $17.4M | $-46.1M | ||
| Q3 25 | $55.0M | $-117.4M | ||
| Q2 25 | $12.4M | $-76.4M | ||
| Q1 25 | $15.5M | $-132.0M | ||
| Q4 24 | $5.6M | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | $19.1M | $-82.2M |
自由现金流CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | $15.8M | $-47.3M | ||
| Q3 25 | $49.8M | $-117.6M | ||
| Q2 25 | $10.8M | $-79.6M | ||
| Q1 25 | $14.7M | $-133.8M | ||
| Q4 24 | $4.5M | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | $16.4M | $-83.4M |
自由现金流率CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | 27.9% | -133.1% | ||
| Q3 25 | 91.3% | -2272.5% | ||
| Q2 25 | 21.2% | -413.9% | ||
| Q1 25 | 30.2% | -907.4% | ||
| Q4 24 | 9.5% | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | 36.5% | -578.5% |
资本支出强度CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 3.5% | ||
| Q3 25 | 9.5% | 4.7% | ||
| Q2 25 | 3.2% | 16.4% | ||
| Q1 25 | 1.5% | 12.4% | ||
| Q4 24 | 2.5% | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | 5.9% | 8.2% |
现金转化率CFFNRXRX
| Q1 26 | — | — | ||
| Q4 25 | 0.86× | — | ||
| Q3 25 | 2.93× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFFN
| Net Interest Income | $52.3M | 91% |
| Noninterest Income | $5.5M | 9% |
RXRX
暂无分部数据
